EUVIMEDEUVIMED entdecken
Crossref

METTL7B Mitigates Hypertension and Vascular Remodeling

Zhenzhen Chen iD, Haizeng Zhang iD, Qiaoxi Yang iD, Luyun Fan, Xilan Dong iD, Qianhui Ling iD, Xinru Guo iD, Fengkai Yue iD, Jiarui Cui iD, Yan Tang iD, Bin Geng iD, Jun Cai iD

Circulation · 2026

DOI: 10.1161/circulationaha.126.079407 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, 2026. Verfasst von Zhenzhen Chen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Anzhen Hospital, Beijing Institute of Heart Lung and Blood Vessel Disease, Capital Medical University, Beijing, China (Z.C., H.Z., Q.Y., L.F.…. Hauptthemen laut MEDLINE: Hypertension, Vascular Remodeling, Methyltransferases. Die Arbeit nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Hypertension is a major risk factor for cardiovascular diseases. RNA N6-methyladenosine (m 6 A) modification is closely linked to hypertension pathogenesis, but key m 6 A-related factors that regulate blood pressure remain unclear. This study aims to identify these regulators and evaluate their therapeutic potential. METHODS: We assessed RNA m 6 A changes and METTL (methyltransferase-like) expression in hypertensive aortas via methylated RNA immunoprecipitation sequencing and RNA sequencing (RNA-seq). Global Mettl7b knockout mice and vascular smooth muscle cell (VSMC)–specific Mettl7b knockin and knockout mice were used to evaluate its in vivo role. Downstream target genes were identified via methylated RNA immunoprecipitation sequencing, enhanced cross-linking and immunoprecipitation sequencing, and RNA-seq. METTL7B activators were screened using molecular docking and surface plasmon resonance and validated in vivo via intraperitoneal injection. RESULTS: Under hypertensive stress, METTL7B expression positively correlated with global RNA m 6 A content, exhibiting concurrent depletion in VSMCs. In vitro biochemical assays revealed that recombinant METTL7B significantly increased RNA m 6 A levels. Crucially, METTL7B overexpression in METTL3 knockout cells robustly upregulated m 6 A levels, definitively establishing METTL7B as a novel, METTL3-independent RNA m 6 A methyltransferase. Physiologically, VSMC-specific Mettl7b ablation exacerbated angiotensin II–induced hypertensive pathogenesis, structural arterial remodeling, and vascular tone, whereas its overexpression exerted potent vasoprotective effects. Mechanistically, METTL7B recruited HNRNPH1 to catalyze m 6 A deposition at the 3′ untranslated region of FILIP1L mRNA, facilitating its maturation. Importantly, the expression of FILIP1L was positively correlated with blood pressure reduction in humans and mice. Elevated FILIP1L downregulated the expression of its binding protein FLNA (Filamin A), reducing F-actin polymerization, attenuating VSMC contractility, and ultimately lowering blood pressure. Furthermore, FILIP1L overexpression reversed the detrimental effects of Mettl7b knockout on hypertension and vascular remodeling, whereas these effects were not rescued by the mutation of FILIP1L’s m 6 A site. Elucidating the upstream pathology, we found that stress-induced KLF4 directly bound the METTL7B promoter, transcriptionally repressing its expression. Finally, the Food and Drug Administration–approved drug netarsudil exerted preventive and therapeutic effects on hypertension and vascular remodeling by activating METTL7B; notably, these therapeutic benefits were completely abolished in VSMC-specific Mettl7b knockout mice. CONCLUSIONS: Collectively, our study identifies a novel RNA m 6 A methyltransferase, METTL7B. The METTL7B-HNRNPH1-FILIP1L axis mitigates hypertension by regulating VSMC dedifferentiation and vascular tone. Targeted activation of METTL7B may emerge as a promising strategy for hypertension.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionVascular RemodelingMethyltransferasesAnimalsMiceMice, KnockoutRNA MethylationMuscle, Smooth, VascularMaleAdenosineHumansEpitranscriptomeMyocytes, Smooth MuscleMice, Inbred C57BLBlood Pressure

Stichwörter der Autor:innen

METTL7Bhypertensionmethyltransferasesvascular smooth muscle cell

Substanzen

MethyltransferasesAdenosine

Autor:innen und Institutionen

  • Beijing Anzhen Hospital, Beijing Institute of Heart Lung and Blood Vessel Disease, Capital Medical University, Beijing, China (Z.C., H.Z., Q.Y., L.F., Q.L., X.G., F.Y., J. Cui, Y.T., J. Cai).
  • State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (Q.Y., X.D., B.G.).

ORCID-Profile: Zhenzhen Chen, Haizeng Zhang, Qiaoxi Yang, Xilan Dong, Qianhui Ling, Xinru Guo, Fengkai Yue, Jiarui Cui, Yan Tang, Bin Geng, Jun Cai

Zitieren

APA

Chen, Z., Zhang, H., Yang, Q., Fan, L., Dong, X., Ling, Q., Guo, X., Yue, F., Cui, J., Tang, Y., Geng, B., & Cai, J. (2026). METTL7B Mitigates Hypertension and Vascular Remodeling. Circulation. https://doi.org/10.1161/circulationaha.126.079407

Vancouver

Chen Z, Zhang H, Yang Q, Fan L, Dong X, Ling Q, et al. METTL7B Mitigates Hypertension and Vascular Remodeling. Circulation. 2026. doi:10.1161/circulationaha.126.079407

BibTeX
@article{Chen2026,
  author = {Chen, Zhenzhen and Zhang, Haizeng and Yang, Qiaoxi and Fan, Luyun and Dong, Xilan and Ling, Qianhui and Guo, Xinru and Yue, Fengkai and Cui, Jiarui and Tang, Yan and Geng, Bin and Cai, Jun},
  title = {METTL7B Mitigates Hypertension and Vascular Remodeling},
  journal = {Circulation},
  year = {2026},
  doi = {10.1161/circulationaha.126.079407}
}
Kostenlos starten →